What is Outset Medical's gross profit margin?

What is Outset Medical's latest dividend and current dividend yield?

What is the market's earnings forecast for Outset Medical next quarter?

What were the key takeaways from Outset Medical's earnings call?

Did Outset Medical beat or miss consensus estimates last quarter?

What does Outset Medical do and what are its main business segments?

What guidance did Outset Medical's management provide for the next earnings period?

What were the key takeaways from Outset Medical’s earnings call?

- **Revenue miss due to timing**: Q3 revenue of $29.4M fell short of expectations due to large deals shifting to 2026. 2025 guidance revised to $115-$120M.
- **Gross margin milestone**: Non-GAAP gross margin reached 39.9%, up 350bps YoY, with a path to 50%.
- **Sales leadership change**: Head of Sales resignation may cause Q4 disruption; search underway for enterprise-focused leader.
- **Clinical validation**: 1M+ treatments show 94% reduction in cardiac events, reinforcing Tablo's value proposition.
- **Cash flow improvement**: Operating cash use down 94% YoY to $6M, with $182M cash on hand.

**【CEO Summary Section】**
 Outset Medical reported Q3 2025 revenue of $29.4 million, reflecting a 3% year-over-year increase. Key highlights include:
- **Shift in deal timing**: Several large enterprise deals, originally forecasted for Q3/Q4, are now expected to close in Q4 2025 and Q1 2026. This timing delay contributed to the revised 2025 revenue guidance of $115-$120 million (down from $122-$126 million).
- **Sales leadership transition**: The resignation of the Head of Sales, effective last week, may cause internal disruption in Q4. The company is conducting a search for a new leader with enterprise sales expertise.
- **Gross margin expansion**: Non-GAAP gross margin reached 39.9%, up 350 basis points year-over-year, driven by manufacturing efficiency improvements.
- **Clinical evidence growth**: Over 1 million Tablo treatments across 750 facilities demonstrated clinical benefits, including a 94% reduction in serious cardiac events at AdventHealth.

**【CFO Financial Commentary】**
- **Revenue breakdown**: Product revenue ($20.6M) and service revenue ($8.9M) both showed modest growth. Recurring revenue ($21.1M) was impacted by delayed orders from large acute care customers.
- **Gross margin details**: Product gross margin improved to 45.7% (from 43.2%), while service margin doubled to 24.8%. Full-year gross margin is expected to remain in the high 30% range.
- **Operating expenses**: Non-GAAP expenses declined 17% to $22.1M, reflecting $80M in cost savings implemented in 2024. Cash usage for the quarter was $6M, down from $100M in 2024.
- **Balance sheet**: $182M in cash provides sufficient liquidity through cash flow breakeven.

**【Q&A Key Highlights】**
- **Guidance rationale**: The $7M reduction in 2025 guidance reflects deal timing delays, sales leadership transition, and cautious forecasting around large customer ordering patterns.
- **Sales leadership criteria**: The company is seeking a leader with enterprise health system experience, capital equipment expertise, and a focus on deal predictability.
- **2026 outlook**: While no formal guidance provided, management emphasized the large addressable market and potential for differentiated growth rates as deal execution improves.
- **Acute care ordering patterns**: Q3 treatment orders lagged utilization by ~50%, but Q4 orders are aligning with usage data. Steps to synchronize ordering with utilization will be implemented in 2026.

Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript

Product

Service and Other

OM

OM fundamentals

You can ask Aime